CVR 39432714Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)FaaborgFounded 9 Mar 2018
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about DeLiver Pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
-20.5K
DKK, annual report 2025
Result
-31.9K
DKK, annual report 2025
Equity
163.2K
DKK, annual report 2025
MOESTRUP HOLDING 2007 ApSCVR 30548094, 25% to under 33.3% of capital and votes
MØLLER HOLDING 2007 ApSCVR 30548167, 25% to under 33.3% of capital and votes
and 2 moreSCIENCE VENTURES DENMARK A/SVenture Capital (Dandex estimate), 25% to under 33.3% of capital and votes
Niels Jonas Heilskov Graversensince 9 Mar 2018
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 3054809425% to under 33.3% of capital and votessince 9 Mar 2018
CVR 3054816725% to under 33.3% of capital and votessince 9 Mar 2018
CVR 3069180625% to under 33.3% of capital and votessince 9 Mar 2018
CVR 2921147725% to under 33.3% of capital and votessince 9 Mar 2018
DeLiver Pharma ApS holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 4209373410% to under 15% of capital and votes1 Feb 2021 to 22 Aug 2024
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 9 Mar 2018.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -20.5K, Operating profit -31.9K, Result for the year -31.9K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 176.4K, Equity 163.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -22 | -18 | 119 | -10 | -20 |
| Operating profit | -147 | -29 | +107 | -22 | -32 |
| Result for the year | -147 | -29 | +107 | -22 | -32 |
| Equity | 139 | 109 | 217 | 195 | 163 |
| Total assets | 150 | 121 | 271 | 206 | 176 |
| Employees (average) | Not reported | Not reported | 0 | 0 | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | n.m.note 1 | n.m.note 1 | n.m.note 1 | -108.7% | n.m.note 1 |
| EBITDA | -22 | -18 | 119 | -10 | -20 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 12note 2 | 0note 3 | 0note 3 | 0note 3 | Not reportednote 4 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for DeLiver Pharma ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 40,000 | None | 40,000 | None | 260,000 | |
| IncreaseCashPaid in 80,000 | None | 80,000 | None | 220,000 | |
| IncreaseCashPaid in 60,000 | None | 60,000 | None | 140,000 | |
| FoundingCashPaid in 260,000, cash price 3.25 | 3.25 | 260,000 | None | 80,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
7 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: c/o Jonas Heilskov Graversen, Sanatorievej 8, 5600 Faaborg
Ny kommune: Faaborg-Midtfyn
Ny adresse: c/o Jonas Heilskov Graversen, Fuglevej 21, 8592 Anholt
Ny kommune: Norddjurs
Ny adresse: Sanatorievej 8, 5600 Faaborg
Ny kommune: Faaborg-Midtfyn
Vedtægter ændret: 12.10.2021
Kapitalforhøjelsen er besluttet den 12.10.2021.
kr. 40.000,00, indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 260.000,00.
Vedtægter ændret: 09.09.2020
Kapitalforhøjelsen er besluttet den 09.09.2020.
kr. 80.000,00, indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 220.000,00.
Vedtægter ændret: 26.02.2020
Kapitalforhøjelsen er besluttet den 26.02.2020.
kr. 60.000,00, indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 140.000,00.
Stiftelsesdato: 09.03.2018.
Seneste vedtægtsdato: 09.03.2018.
Kapital:
kr. 80.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 60.000,00 til kurs 100,00, fuldt indbetalt.Indbetalt kontant kr. 20.000,00 til kurs 1.000,00, fuldt indbetalt.
Stiftere:
CVR-NR. 29211477 SCIENCE VENTURES DENMARK A/S, Cortex Park 26, 5230 Odense M, den 09.03.2018, CVR-NR. 30548094 MOESTRUP HOLDING 2007 ApS, Jørgen Brønlunds Vej 14, 8200 Aarhus N, den 09.03.2018, CVR-NR. 30548167 MØLLER HOLDING 2007 ApS, Hørmarks Allé 8, 8240 Risskov, den 09.03.2018, CVR-NR. 30691806 PHIDEAS ApS, Tesdorpfsvej 12, 5000 Odense C, den 09.03.2018.
Bestyrelse:
Jens Kristian Damsgaard (formand), den 09.03.2018, Niels Jonas Heilskov Graversen, den 09.03.2018, Søren Kragh Moestrup, den 09.03.2018, Holger Jon Møller, den 09.03.2018.
Direktion:
Niels Jonas Heilskov Graversen, den 09.03.2018.
Selskabet tegnes af en direktør og bestyrelsesformanden i forening eller af den samlede bestyrelse i forening..
Første regnskabsår:
09.03.2018 - 31.12.2018.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med medicinsk udvikling samt enhver i forbindelse hermed stående virksomhed.
P-number 1023461877Sanatorievej 8, 5600 Faaborg